Final Call for Raptiva Recall

June 22nd, 2009. By janem

The complete recall of Genentech’s psoriasis drug Raptiva throughout the US and some countries of the European Union will be finalized this week, after sales were suspended in April of this year due to the risk of serious Raptiva side effects, including a fatal brain infection known as progressive multifocal leukoencephalopathy (PML).

Although the overall risk of PML for patients on Raptiva is low, it appears to be increased in long-term users of the drug and in those with compromised immune systems. But the FDA announced that Raptiva would no longer be available in the United States by June 8, 2009. So that means a patient could get a prescription in June and potentially take Raptiva for at least 4 months or so after sales were initially suspended.

 I don’t get it: if the amount of time a patient is on Raptiva is a crucial factor in developing PML, why was this drug phased out slowly instead of being wiped off the market in one fell swoop?

Tags: Raptiva, Raptiva PML Brain Infection

This was posted on Monday, June 22nd, 2009 at 6:07 pm and is filed under Drugs/Medical . Feel free to respond, or trackback. Read our comments policy.